BioCentury
ARTICLE | Politics, Policy & Law

Hastings elected BIO chair, to continue reinvention of the trade association

June 14, 2021 10:58 PM UTC

With the election of Paul Hastings as chair of its board of directors, BIO is signaling its determination to continue a reinvention of the trade association that started two years ago with the election of Jeremy Levin as chair and was cemented with the selection in May 2020 of Michelle McMurry-Heath as its president and CEO.

Hastings, president and CEO of Nkarta Inc. (NASDAQ:NKTX), has ridden the biotech rollercoaster, having served as chairman and CEO of OncoMed Pharmaceuticals Inc.; president and CEO of QLT Inc.; president and CEO of Axys Pharmaceuticals; and president and CEO of LXR Biotechnology. His earlier career included stints as president of Genzyme Therapeutics Europe and president of Genzyme Therapeutics, as well as marketing and sales positions at Synergen Inc. and Roche (SIX:ROG’ OTCQX:RHHBY)...